Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

However, the difference in TFR between the groups did not reach statistical significance ( p = 0.07, Supplementary Fig. 2 ) The probability of maintaining TFR was higher in patients with a longer first TFR (more than six months) compared to those with a short first TFR (less than six months).

also in 111,027 other papers